 Amgen announced that the European Commission (EC) has granted marketing authorization for XGEVA® (denosumab) for the prevention of skeletal-related events (SREs) (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with bone metastases from solid tumors. |
XGEVA(R) (Denosumab) Granted Marketing Authorization in the European Union
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment